A Parkinson Disease Primer



March 5, 2019
Elizabeth Slow MD PhD
TWH: Movement Disorders
Neurologist







Faculty/Presenter Disclosure

- Faculty: Elizabeth Slow
- Relationships with financial sponsors:
 - Civitas Pharmaceuticals (part of a clinical trial)







Disclosure of Financial Support

- This program has NOT received financial support other than the support of the MOHLTC
- This program has NOT received in-kind support
- Potential for conflict(s) of interest:

None to be disclosed







Mitigating Potential Bias

The information presented in this CME program is based on recent information that is explicitly "evidence-based".

This CME Program and its material is peer reviewed and all the recommendations involving clinical medicine are based on evidence that is accepted within the profession; and all scientific research referred to, reported, or used in the CME/CPD activity in support or justification of patient care recommendations conforms to the generally accepted standards







Objectives:

- PD Timeline:
- i. Early Stage
- ii. Mid Stage
- iii. Late Stage
- Treatment: Motor and Non-motor Symptoms at each stage







PD Demographics


- Prevalence 1% over the age of 60 (incidence increases with age)
- Male: Female ratio 1.5:1
- Mean age of onset =65
- 90% sporadic, 10% genetic
- Increased risk with head injury, pesticide exposure
- Decreased risk with smoking and caffeine consumption, Appendix removal?







PD Diagnosis



Adapted from Grimes et al., Canadian Guidelines on Parkinson Disease Treatment. Can J Neurol Sci. 2012; 39: Supp 4. S1-S30.







Parkinsonism Differential

Parkinsonism	Distinguishing Features
Multiple system atrophy	Prominent dysautonomia, cerebellar dysfunction (ataxia), pyramidal tract signs, stimulus- sensitive myoclonus, respiratory symptoms (apnea, stridor), prominent dysarthria
Progressive supranuclear palsy	Early falls, vertical supranuclear gaze palsy, cognitive and behavioral changes
Corticobasal degeneration	Cognitive dysfunction, apraxia, alien limb, cortical sensory loss; asymmetrical rigidity, dystonia; stimulus-sensitive myoclonus
Dementia with Lewy bodies	Dementia, visual hallucinations, fluctuating level of consciousness, sensitivity to neuroleptics, REM sleep behavior disorder
Normal pressure hydrocephalus	Cognitive impairment, urinary symptoms, lower-body parkinsonism ("gait apraxia")
Vascular parkinsonism	"Lower-body parkinsonism," additional neurologic signs (e.g., spasticity, weakness)
Drug-induced parkinsonism	Can have all the features of classic parkinsonism of PD, including rest tremor; generally symmetrical; can be accompanied by other drug-induced movement disorders (e.g.,

Slow EJ, Lang AE. Neurology. Parkinsonism and Related Disorders. In: Singh AK, editor(s). Scientific

Supportive criteria for the diagnosis of PD

- Unilateral onset
- Rest tremor
- Progressive
- Persistent asymmetry primarily affecting side of onset
- Excellent response(70%-100%) to levodopa
- Severe levodopa-induced dyskinesia
- Levodopa response for 5 years or more
- Clinical course of 10 years or more

Jankovic. J Neurol Neurosurg Psychiatry 2008;79:368-376







Case

ID: 65 M teacher, healthy, no meds

HPI: 3 year progressive R hand rest tremor, stiffness of right shoulder, mild difficulties using R hand, occasional dragging R leg

5 year history of olfactory loss, 10 year history of RBD

No autonomic, cognitive, psychiatric

Exam: mild increased tone right, rest tremor R hand, bradykinesia R hand, decreased arm swing R

Normal EOMs, no orthostatic drop








Parkinson Disease: Early

Motor



Tremor
Rigidity
Akinesia/Bradykinesia

Non-Motor







Constipation


Pre-Motor













Adapted from Kalia and Lang. Parkinson Disease Treatment. Lancet. 2015; 386: 896-912



Adapted from Kalia and Lang. Parkinson Disease Treatment. Lancet. 2015; 386: 896-912



Adapted from Kalia and Lang. Parkinson Disease Treatment. Lancet. 2015; 386: 896-912

Case

ID: 60 M teacher, healthy, no meds

HPI: 3 year progressive R hand rest tremor, stiffness of right shoulder, mild difficulties using R hand, occasional dragging R leg

10 year history of olfactory loss, 5 year history of RBD

No autonomic, cognitive, psychiatric

Exam: mild increased tone right, rest tremor R hand, bradykinesia R hand, decreased arm swing R

Normal EOMs, no orthostatic drop







Case

ID: 60 M teacher, healthy, no meds

HPI: 3 year progressive R hand rest tremor, stiffness of right shoulder, mild difficulties using R hand, occasional dragging R leg

10 year history of olfactory loss, 5 year history of RBD

No autonomic, cognitive, psychiatric

Exam: mild increased tone right, rest tremor R hand, bradykinesia R hand, decreased arm swing R

Normal EOMs, no orthostatic drop

What is the recommended initial therapy?








PD Motor Treatment: Medications

- 1. Levodopa:
- 2. Dopamine Agonists: pramipexole, ropinirole, rotigitine (patch)
- 3. Monoamine-B Inhibitors: selegiline, rasagiline
- 4. COMT inhibitor: entacapone
- 5. Anti-cholinergics: e.g. trihexyphenidyl









PD Motor Treatment: Age>65

- 1. Levodopa
- 2. Dopamine Agonists: pemipexole, ropinirole, rotigitine (patch)
- 3. Monoamine-B Inhibitors: selegiline, rasagiline
- 4. COMT inhibitor: entacapone
- 5. Anti-cholinergics: e.g. hexyphenidyl







Treatment: Levodopa

Levodopa: 50 Years of a Revolutionary Drug for Parkinson Disease

Available as:

Stanley Fahn, MD¹ and Werner Poewe, MD²

- Sinemet (with carbidopa), Prolopa (with benserazide)
- IR preparation or CR; (ER in US- Rytary)
- Levodopa/carbidopa intestinal gel: Duodopa
- Adverse effects:
 - Behavioural complications
 - Dyskinesias and motor fluctuations
 - Nausea/GI
 - Orthostatic Hypotension
 - Worsening hallucinations/behavioural







Treatment: Dopamine Agonist

- Drugs: Pramipexole, Ropinirole, Rotigitine
- Less well tolerated in elderly patients
- Adverse effects:
 - Impulse Control Disorder***: hypersexuality, hyperphagia, excessive gambling/shopping (up to 15% of patients)
 - Nausea/GI
 - Orthostatic Hypotension
 - Worsening hallucinations
 - Ankle edema
 - Sleep attacks







Treatment: Enzyme Inhibitors

1. Monoamine B (MAOB)-Inhibitors: block breakdown of levodopa and patient's intrinsic dopamine

Rasagiline, Selegiline

Theoretical risk of serotonin syndrome with SSRI use but exceedingly rare

2. COMT-Inhibitors: block breakdown of levodopa ONLY (therefore adjunctive therapy with levodopa ONLY)

Entacapone; Stalevo (single pill with levodopa/carbidopa/entacapone)

Side effects: Diarrhea 5% - need to stop drug







Back to the Case...

ID: 65 M teacher with 3 year history of possible PD

HPI: Started on levodopa with good benefit but feels nausea with every dose









Parkinson Disease- Early





Medication Complications



Peripheral:

Nausea; orthostatic hypotension







Levodopa Peripheral Side Effects

- Nausea/vomiting can be a complication of starting therapy in up to 15% of patients
- Orthostatic hypotension can be worsened

Treatment:

- 1. Take with food (e.g. cracker)
- 2. Additional dose of carbidopa with levodopa
- 3. Domperidone 30 minutes prior to levodopa dosing (*** associated with small increased risk in ventricular arrhythmias, sudden cardiac

(*** associated with small increased risk in ventricular arrhythmias, sudden cardiac death- 30 mg per day max and not for use in certain populations – e.g. prolonged Qt, CHF, severe liver disease)

***Domperidone Maleate - Association with Serious Abnormal Heart Rhythms and Sudden Death (Cardiac Arrest) - For Health Professionals

Case... five years later

ID: 70 M

Dx: Probable PD

Started on levodopa with excellent response.

Increasing levodopa overtime to 2tabs q4H with good response

Now noticing at 3.5 hours very immobile until next dose "kicks in"


Also, at middle of dose has "wriggly movements" which are bothersome









Parkinson Disease-Mid





Medication Complications



Peripheral: N/V, OH


Central: Motor fluctuations and dyskinesias







Motor Fluctuations in PD



Adapted from: Obeso JA et al. In: Olanow CW, Obeso JA, eds. Beyond the Decade of the Brain. Vol 2.







Treatment of Motor Fluctuations:

Wearing Off:

- 1. Addition of COMT or MAO-B inhibitor: reduce off time by 1.5 hr/day (Level A)
- 2. Addition of Dopamine agonist: reduce off time by 15% (Level B)
- 3. Change of timing/amount of levodopa

Dyskinesias:

- 1. Amantadine- NOT for use in elderly (confusion/hallucinations)
- 2. Variation of the above

Advanced Therapies!!

Grimes et al., Canadian Guidelines on Parkinson Disease Treatment. Can J Neurol Sci. 2012; 39: Supp 4. S1-S30







Advanced Therapies: Treatment of Medication-Resistant Motor Fluctuations*

1. Surgery: Deep Brain Stimulation



2. Levodopa-carbidopa intestinal gel (LCIG/duodopa)

Approval for use and drug benefit coverage Ontario 2014 (used in Europe since 2004)

*Requires referral to a Movement Disorders Centre in Toronto (TWH), Hamilton, London, Ottawa

DBS Candidates



LCIG Candidates


es

- PD diagnosis
- Levodopa Responsive (30-40%)
- -Medically healthy
- -No dementia
- No psychosis
- No unstable depression
- -<70 (75?)

- PD diagnosis
- Levodopa Responsive (30-40%)
- Medically healthy
- -MCI/mild dementia OK
- Mild psychosis OK
- -Mild depression OK

-No age limit

DBS, LCIG Benefits – decrease ON time with bothersome dyskinesia and OFF time



Deutschl and Agid, Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurol 2013. 12:1025-34.

Olanaw et al., Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology. 2014. 13 (2) 141-149

Case... eight years later

ID: 73 M

STN DBS 2 years ago with good benefit on motor fluctuations, dyskinesias

On levodopa, entacapone

Has had a few falls in the past month

His voice is soft and his wife finds it difficult to hear him at times








Parkinson Disease-Late

Motor



Tremor Rigidity Akinesia/Bradykinesia

Hypophonia Postural Instability Gait Disorder (Freezing) Dysphagia







Non-Medical Management

SPEECH

- Speech therapy
- Singing

FALLS

- Walker/Wheel chair
- Occupational Therapist assessment
- Rule out hypotension
- PT, Tai Chi, Exercise









urtesy Veronica Bruno MD

Case... ten years later

ID: 75 M

STN DBS 4 years ago with good benefit on motor fluctuations, dyskinesias

On levodopa, entacapone

Has difficulties standing up at times, 1 syncope

Severe constipation

Also, his wife feels he is repeating himself and misplacing items








Parkinson Disease-Late

Motor




Tremor Rigidity Akinesia/Bradykinesia

Postural Instability/Gait (FOG)

Dysphagia

Non-Motor




1. Cognitive/Psychiatr ic

2. Autonomic





Medication Complications



Peripheral: N/V, orthostatic hypotension

Central: Motor complications

Central: Behavioural

PD Motor Treatment: Advanced Disease

- Development of levodopa-resistant motor symptoms e.g. freezing of gait, instability, falls
- Previously responsive symptoms may become less levodopa-responsive
- Increased likelihood of levodopa-induced complications in advanced disease e.g. hallucinations, behavioural changes
- BUT... many patients can continue to have levodoparesponsive parkinsonism in advanced disease
- There may be non-motor features that also respond to levodopa e.g. anxiety, pain

Swallowing in Advanced PD

- Videofluoroscopy swallowing assessment
- Coughing on liquids or solids is common
- Dietary modification often necessary use of thickeners
- Careful hand feeding can be as effective as PEG for nutritic Feeding Choices for People with

Advanced Parkinson's Disease



UHN

Information for patients, families and caregivers


http://www.uhn.ca/PatientsFamilies/Health_Information/Health_Topics/Documents/Feeding_Choices_Advanced_Parkinson_Disease.pdf








PD: Non-motor



- 1. Dementia
- 2. Hallucinations
- 3. Depression
- 4. Anxiety
- 5. Apathy



- Constipation
- Urinary Symptoms
- OrthostaticHypotension
- 4. Erectile Dysfunction
- 5. Drooling







- REM Sleep
 Behaviour
 Disorder
- 2. Insomnia
- Excessive Daytime Sleepiness



Psychosis/Hallucinations

- Tend to be well-formed animals or people
- Increased likelihood with disease duration (up to 70% with 20 years disease) and in the setting of dementia
- Other risks: vision problems, medications, infections

Treatment:

- Rule out infections/other causes
- Stop offending medications (anticholinergics; amantadine>DA>levodopa)
- Medications: quetiapine, cholinesterase inhibitors, clozapine
- Not all hallucinations require treatment

Psychosis/Hallucinations

- Tend to be well-formed animals or people
- Increased likelihood with disease duration (up to 70% with 20 years disease) and in the setting of dementia
- Other risks: vision problems, medications, infections

Treatment:

- Quetiapine and Clozapine are the only two "safe" anti-psychotics in PD and related disorders amantagine>DA>ievogopa)
 - Medications: quetiapine, cholinesterase inhibitors, clozapine
 - Not all hallucinations require treatment







Memory Loss/Dementia

Likelihood increases with disease duration (up to 80% at 20 years duration)

Characterized by slowing of thinking, difficulties with decision making, less flexible thinking; eventual memory problems

Treatment

- Stop offending medications (anticholinergics, TCAs amantadine, dopamine agonists)
- Medication: Acetyl-cholinesterase Inhibitors,
 Memantine

Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Neurotherapeutics. 2014







Anxiety and Depression

- Can predate PD
- PD can cause or worsen existing depression and or anxiety

- Treatment:

- Psychotherapy
- Medications (TCA-for depression; SSRI, SNRI)
- ECT for severe depression
- "Secondary anxiety disorder:" Associated with "offperiods" or low-levodopa levels: adjust levodopa dosing

Autonomic Dysfunction

SIALORRHEA

Candy, gum

Meds: Atrovent, atropine, Botulinum Toxin injections

CONSTIPATION

Make certain the Bowel Routine is working (senokot, lactulose, PEG)

URINARY PROBLEMS

Modifications: Urinal/commode at bedside

- Appropriate garments and bedsheets
- Condom catheters

Medications: Variety, many with anticholinergic side effects, newer meds with less side effects; botox

ORTHOSTATIC HYPOTENSION

Increase water intake, salt in the diet if possible Fludrocortisone, midodrine, domperidone





Sleep

RBD

Bed safety

Medications: melatonin, clonazepam, quetiapine

Excessive Daytime Sleepiness

Check Blood pressure!, review medications, review overnight sleep Treat any of the above Medication: Modafinil, Methylphenidate (occasional)

Insomnia

Sleep Hygiene Medications:

Initiation: Melatonin, zopiclone

Maintenance: Sinemet CR, treat nocturia







Dopaminergic Medication Behavioural Complications

Impulse control disorder	Includes pathologic gambling, hypersexuality, compulsive shopping, and binge eating
Punding	Repetitive, often purposeless stereo- typed behaviors (e.g., continual handling or sorting of objects)
Dopamine dysregulation syndrome	Compulsive overuse of dopaminergic therapy (above what is necessary for treatment of motor symptoms)

Treatment: Decrease dopaminergic medication

Pain in PD

- Prevalence ranges from 40% to 85%, frequently located in the lower limbs
- ½ of all PD patients complain about MSK pain, which has likely worsened with deconditioning and lack of rehabilitation
- Pain may fluctuate with on/off periods (levodopa-responsive?)
- Only 52.4% of PD patients with pain used analgesics, most often non-opioids
- No foundation of evidence for PD pain treatment
- Can respond to traditional pain therapies (e.g. acetaminophen, ROM exercise)
- Opioids problematic due to side effects (constipation, psychoactive metabolites) but occasionally useful

Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012







Questions?

elizabeth.slow@uhn.ca







